BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Redburn Atlantic
Equities research analysts at Redburn Atlantic began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $50.00 price target on the stock. Redburn Atlantic’s target price suggests a potential upside of 51.42% from the company’s current […]
Equities research analysts at Redburn Atlantic began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $50.00 price target on the stock. Redburn Atlantic’s target price suggests a potential upside of 51.42% from the company’s current […]
